Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebo-controlled trialArticle Published on 2022-11-012022-11-15 Journal: Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] 95% confidence interval Administered adverse event approved assessment booster booster dose booster vaccination clinical trials Course COVID-19 COVID-19 vaccination COVID-19 vaccine cross-neutralization cross-neutralization. Day double-blind Effect fatigue Heterologous homologous humoral immunogenic immunogenicity incidence injection site pain Local Neutralizing antibodies neutralizing antibody outcome participant Participants Placebo placebo-controlled primary immunogenicity Randomized randomized placebo-controlled trial Recombinant spike protein reported robust Safe Safety safety profile saline placebo SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variants Serious Adverse Event Serious Adverse Events Seroconversion seroconversion rate shown SpikoGen subunit the placebo group Trial Vaccine was performed [DOI] 10.1111/imm.13540 PMC 바로가기
Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled TrialArticle Published on 2022-10-062022-11-15 Journal: The Journal of Nutrition [Category] COVID19(2023년), SARS, 바이오마커, [키워드] adhesion molecules age anti-inflammatory effect Antigen assigned baseline Biomarker Blood BMI C-reactive protein CDC chronic condition coin toss Concentration conducted Controlled coronavirus disease covariates COVID-19 COVID-19 complications COVID-19, SARS-COV-2 Cytokines diagnosed with COVID-19 Diagnosis dietary supplements double-blind dysregulated immune response Effect exacerbate ferritin group Health IL-1β IL-2 IL-6 implicated indicated individual infected with COVID-19 infections infectious conditions Inflammation inflammatory mediator intercellular Linear regression model mechanism Multiple outcomes P-selectin palmitoylethanolamide palmitoylethanolamide. participant Placebo placebo tablet positive test result Primary outcome produced proinflammatory promote randomized placebo-controlled trial Randomly receive reduced reported RT-PCR secretion severity Sex significantly stratified treatment effect [DOI] 10.1093/jn/nxac154 PMC 바로가기
Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populationsArticle Published on 2022-09-012022-11-15 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 진단, [키워드] Advax-CpG adverse event antibody Cellular immune response composed conducted COVID-19 COVID-19 vaccine dose double-blind fatigue geometric mean concentration humoral incidence injection site pain Mild outcome participant phase Phase 2 phase 2 trial Placebo placebo-controlled Population primary immunogenicity Protein Randomized randomized placebo-controlled trial receive Safety safety profile SARS-CoV-2 SARS-CoV-2 spike protein second dose Serious Adverse Event Seroconversion seroconversion rate seronegative seropositive SpikoGen subunit subunit protein vaccine. the placebo group vaccination Vaccine Volunteer were recorded [DOI] 10.1016/j.cmi.2022.04.004 PMC 바로가기
The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 – a double-blind, randomized placebo-controlled trialRandomized Controlled Trial Published on 2022-09-012022-10-04 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 신약개발, 임상, 치료법, 치료제, [키워드] 95% confidence interval Anti-SARS-CoV-2 Activity antiparasitic antiviral properties COVID-19 Culture cultures cycle threshold double-blind double-blinded early treatment Endpoint evaluated Infectivity Infectivity duration Ivermectin ivermectin group less Mild multivariable logistic regression Nasopharyngeal swab negative test Odds ratio Patient patients with COVID-19 per-protocol Placebo positive primary endpoint Primary outcome randomized placebo-controlled trial reached receiving recruitment reduce reduction reflected SARS-CoV-2 screened supported the placebo group Transmission Trial viability viral cultures Viral cultures. Viral load was obtained [DOI] 10.1016/j.ijid.2022.07.003 PMC 바로가기 [Article Type] Randomized Controlled Trial
Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trialResearch article Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 임상, [키워드] antibodies benefit clinical conducted convalescent plasma Convalescent plasma therapy Course COVID-19 death determine died disease severity double blind duration of symptoms Effectiveness Endpoint enrolment Follow-up hazard ratio high-risk patient highest Hospital admission Hospitalized ICU admission IMPROVE in viral median age multicentre objective Odds ratio Older Outpatient outpatients Patient PCR primary endpoint randomization randomized placebo-controlled trial randomized trial recruitment Result risk factor RNA secondary severe COVID-19 Symptom symptom duration symptom onset symptomatic Symptoms the disease therapy for COVID-19 vaccination Viral RNA [DOI] 10.1016/j.cmi.2022.08.005 [Article Type] Research article
Efficacy of tadalafil on improvement of men with erectile dysfunction caused by COVID-19: A randomized placebo-controlled trialResearch article Published on 2022-08-012022-10-05 Journal: Asian Journal of Urology [Category] 임상, [키워드] acute respiratory distress administration baseline caused Complete complete recovery control group coronavirus disease COVID-19 criteria Daily dysfunction effective Efficacy Erectile dysfunction function Health index intervention group men objective Outpatient Patient Placebo polymerase chain Prevalence questionnaire randomized placebo-controlled trial Result risk Safe Sexual function significantly higher subsequent syndrome Tadalafil the patient Treatment was performed [DOI] 10.1016/j.ajur.2022.05.006 [Article Type] Research article
Safety and tolerability of hydroxychloroquine in health care workers and first responders for the prevention of COVID-19: WHIP COVID-19 StudyRandomized Controlled Trial Published on 2022-03-012022-10-04 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 임상, [키워드] acquisition Adverse adverse event ARMS Autoimmune diseases cardiovascular risk Chemoprophylaxis confirmed COVID-19 case COVID-19 determine Efficacy end point enrolled evaluate event Future group HCQ HCW Health care Health care worker health care workers high-risk population highest Hospitalization Hydroxychloroquine hydroxychloroquine treatment Intervention Laboratory occurred participant Placebo placebo-controlled clinical study polymerase chain positive prospective cohort Randomized randomized placebo-controlled trial randomized trial required Responder responders Result risk Safe Safety SARS-CoV-2 SARS-COV-2 infection the epidemic Tolerability Trial was used [DOI] 10.1016/j.ijid.2021.12.343 PMC 바로가기 [Article Type] Randomized Controlled Trial
Targeting the Endothelium in the Treatment of COVID-19 Early Clinical Stages: Results of a Randomized Placebo-Controlled TrialConference abstract Published on 2021-11-232022-10-05 Journal: Blood [Category] 임상, [키워드] 95% CI 95% confidence interval analyzed Antithrombotic assigned benefit bleeding C reactive protein C-reactive protein calculated calculator Care caused clinical clinical disease Clinical stage Cluster Comorbidity Complication concerning conducted COVID-19 COVID-19 patient COVID-19 patients CRP D-dimer D-dimer level D-dimer value determine difference Disease progression dose Effect Endothelial cell Endpoint evaluate the effect evaluated Fewer patient First wave Follow-up healthcare high risk hospital Hospital admission Inclusion inclusion criteria induce Intervention Kaplan-Meier curve limitation lockdown major bleeding medication Mortality normally distributed oral anticoagulant oxygen support participant Patient patients required hospitalization per-protocol analysis percentage performed physician Placebo pleiotropic Primary outcome progression randomized placebo-controlled trial Randomly receive reduced required responsible Result risk SARS-CoV-2 Serum level serum levels Seven Side effects significantly higher Standard of care student suggested sulodexide supplemental oxygen supplemental oxygen support synergistic t-test T-tests target targeting the placebo group Thromboembolic events treat analysis Treatment Trial Vascular Vascular endothelium was used were assessed were blinded Wilcoxon test [DOI] 10.1182/blood-2021-151814 [Article Type] Conference abstract
Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years – United States, June-September 202112-18세 사이의 COVID-19 입원에 대한 Pfizer-BioNTech mRNA 예방 접종의 효과 - 미국, 2021년 6월-9월Article Published on 2021-10-222022-09-11 Journal: Morbidity and Mortality Weekly Report [Category] 변종, [키워드] 95% CI 95% confidence interval Against age B.1.617.2 case-control study children controls COVID-19 COVID-19 hospitalization COVID-19 vaccine Delta demonstrated dose drug effective Effectiveness Efficacy FDA food Food and Drug Administration highest hospital Hospitalized hospitalized patients median age mRNA obesity pandemic pediatric Person Pfizer Pfizer-BioNTech predominant PROTECT randomized placebo-controlled trial reached severe COVID-19 the median United States vaccination Vaccine variant Year Youth [DOI] 10.15585/mmwr.mm7042e1 PMC 바로가기 [Article Type] Article
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial청소년 및 노인의 SARS-COV-2 재조합 스파이크 단백질 백신 (NVX-COV2373)의 상이한 용량 요법 : 2 상 무작위 위약 대조 시험Clinical Trial Published on 2021-10-012022-08-13 Journal: PLoS Medicine [Category] Biochemistry, MERS, SARS, 임상, 진단, [키워드] 95% CI 95% confidence interval accumulate addition Administered Adults adverse events age Anti-spike Antibody Response assessments assigned composed conducted convalescent sera coronavirus Day dose dose regimen Efficacy Endpoint Enrollment exceeded Follow-up Formica Frequency full-length SARS-CoV-2 geometric mean geometric mean titer geometric mean titers GMTs group groups identify IgG immune persistence immune response immune responses immunogenic immunogenicity Immunoglobulin Immunoglobulin G include inhibitory concentration intensity intramuscular dose lack limitation Matrix-M1 adjuvant median Mild mild to moderate moderate neutralizing antibody Neutralizing antibody response neutralizing antibody responses NVX-CoV2373 occurred less Older Older adults participant Participants Phase 1 Phase 2 Placebo placebo-controlled placebo-controlled trial primary endpoints Protein Randomized randomized placebo-controlled trial Randomly reactogenicity receive Recombinant spike protein regimen researcher respiratory Respiratory Coronavirus robust safety follow-up SARS-CoV-2 second dose second vaccination secondary endpoint seroconversion rate seroconversion rates severity short duration spike glycoprotein spike glycoproteins Spike protein Support The United States These data Tolerability Treatment Trial Trial registration trimeric United States USA vaccination Vaccine vaccine group wild-type virus [DOI] 10.1371/journal.pmed.1003769 PMC 바로가기 [Article Type] Clinical Trial